Blue Jet Healthcare's FY26 profit declined 18.80% to ₹247.82 crore on lower revenues. However, operating cash flow significantly improved, rising over six-fold. The company faces tax litigation and project delays.
Blue Jet Healthcare FY26 Financials Show Profit Decline Amidst Strong Cash Generation
Blue Jet Healthcare reported a 18.80% decline in profit for the financial year ending March 31, 2026, with profit for the year at ₹247.82 crore. This comes as revenue from operations also saw a decrease of 8.03% to ₹947.32 crore.
Reader Takeaway: Profitability dips while operating cash flow shows robust growth; tax litigation remains a concern.
What just happened
Blue Jet Healthcare’s financial year 2025-26 results indicate a downturn in profitability and revenue compared to the previous year. Profit for the year fell to ₹247.82 crore from ₹305.20 crore in FY25. Revenue from operations also decreased to ₹947.32 crore from ₹1,030.00 crore in FY25. Despite these declines, the company reported a substantial 630.22% increase in operating cash flow, reaching ₹334.15 crore compared to ₹45.76 crore in FY25.
Why this matters
The reduced profitability and revenue raise concerns about the company's top-line growth and earnings potential. The significant rise in operating cash flow, however, is a positive sign, indicating better cash generation from its core operations, which could support future investments or debt reduction. The outcome of tax litigation and the progress on the Mahad project are critical for future performance.
The backstory
Blue Jet Healthcare is involved in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals. The company had previously reported strong growth, and this year’s performance marks a shift.
What changes now
Investors will be closely watching the company's strategy to address the revenue and profit decline. The improved cash flow provides a cushion, but the company needs to navigate significant risks, including tax demands and project execution.
Risks to watch
The company is facing a tax litigation demand of ₹193.39 crore under Section 156 of the Income Tax Act, 1961, for Assessment Years 2020-21 to 2023-24. A partial payment of ₹16.5 crore has been made under protest to secure a stay. Auditors also highlighted concerns regarding internal control documentation, the manual maintenance of inventory records until December 2025, and delays in the backward integration project at Mahad, Maharashtra.
Peer comparison
(No peer comparison data available in the filing).
Context metrics (time-bound)
- Revenue from Operations (FY26): ₹947.32 crore (down 8.03% from FY25)
- Profit for the Year (FY26): ₹247.82 crore (down 18.80% from FY25)
- Basic EPS (FY26): ₹14.29 (down 18.76% from FY25)
- Operating Cash Flow (FY26): ₹334.15 crore (up 630.22% from FY25)
- Mahad project capex incurred: ₹179.56 crore as of March 31, 2026.
What to track next
Investors should monitor the resolution of the ₹193.39 crore tax demand and the improvements in internal control documentation. Progress on the delayed Mahad backward integration project and any updates on regulatory or tax proceedings will be crucial.